Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer
Patients with recurrent or metastatic cervical cancerï¼Œand will be treated with GLS-010.
Cervical Cancer
DRUG: GLS-010
Objective response rate, Based on an independent image assessment board, within 27 Months after patient enrolled
PFS, meaningful benefit in PFS based on RECIST 1.1, within 27 Months after patient enrolled|DCR, meaningful benefit in DCR based on RECIST 1.1, within 27 Months after patient enrolled|DOR, meaningful benefit in DOR based on RECIST 1.1, within 27 Months after patient enrolled|OS, Overall survival, within 3 years after patient enrolled.|TTR, meaningful benefit in TTR based on RECIST 1.1, within 27 Months after patient enrolled
Open, uncontrolled, multi-center, phase II study.